Opendata, web and dolomites

Lumiblast SIGNED

A paradigm shift in cancer therapy – using mitochondria-powered chemiluminescence to non-invasively treat inaccessible tumours

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Lumiblast project word cloud

Explore the words cloud of the Lumiblast project. It provides you a very rough idea of what is the project "Lumiblast" about.

cell    impressive    invasive    chemistry    deep    gbm    therapy    sme    formulation    origins    killing    athens    mainly    georgios    models    expertise    activated    cm    light    activating    oslash    luminescence    jan    tissue    concerted    photodynamic       leader    cranium    photomedicine    ceo    oslo    brain    photons    interdisciplinary    record    action    renowned    avoiding    cancers    treat    efficient    inaccessible    clinic    tumour    localized    lamp    ltd    glioblastoma    hanne    vision    limited    sited    nature    act    upv    breakthrough    valencia    nnensen    university    lumiblast    team    inside    track    world    least    treatments    lesion    miranda    spread    polytechnic    uio    tumors    uoa    sources    penetration    cells    tumor    headed    individual    hospital    multiforme    aggressive    pdt    proof    ksl    knight    ros    photon    surgery    pharmaceutical    animal    small    photosensitizers    cultures    form    external    margin    vougioukalakis    collective    solid    coming    scientific    miguel    extracellular    practically    usually    synthetic    ous    specialized    resection    agents    utilized    eliminate    invasiveness    group    berg    hitherto    clinically    location    chemiluminescence    photosensitive    limitation    completely    incurable    photochemistry   

Project "Lumiblast" data sheet

The following table provides information about the project.

Coordinator
OSLO UNIVERSITETSSYKEHUS HF 

Organization address
address: KIRKEVEIEN 166 TARNBYGGET
city: OSLO
postcode: 450
website: http://www.oslo-universitetssykehus.no

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website http://www.lumiblast.eu
 Total cost 3˙031˙375 €
 EC max contribution 3˙031˙375 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-2014-2015-RIA
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) coordinator 1˙306˙375.00
2    KNIGHT SCIENTIFIC LIMITED UK (PLYMOUTH DEVON) participant 477˙500.00
3    UNIVERSITAT POLITECNICA DE VALENCIA ES (VALENCIA) participant 424˙375.00
4    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 413˙125.00
5    UNIVERSITETET I OSLO NO (OSLO) participant 410˙000.00

Map

 Project objective

Brain cancers such as glioblastoma multiforme (GBM) are practically incurable due to their location, invasiveness and highly aggressive nature. The use of light-based treatments of GBM by activating tumor-localized photosensitizers, such as in photodynamic therapy (PDT) has been clinically evaluated, but with limited success. This is mainly due to the limited penetration of light into tissue and the efficient spread of tumor cells typically up to at least 2 cm from the resection margin. Moreover, the existing photon based treatments (photodynamic therapy) are highly invasive and usually require open-cranium surgery, due to the need for external light sources. In the Lumiblast project the photons are produced inside the tumor cells in the form of chemiluminescence avoiding the major limitation of using external light to treat solid, deep-sited and inaccessible tumors. The principle utilized in Lumiblast may also be relevant for cancers of other origins. Due to its nature Lumiblast is expected to act on individual cells, rather than the collective lesion; it could thus completely eliminate the hitherto incurable GBM. Each GBM cell is expected to become a small lamp providing the light required for the photosensitive agents to become activated, killing the tumour cells from the inside. Lumiblast requires a concerted interdisciplinary action. The project coordinator (Berg’s group, Oslo University Hospital, OUS) is world renowned in PDT and photomedicine, while the team from the University of Athens (Georgios Vougioukalakis’ group, UoA) is up and coming with high expertise in synthetic chemistry. The Polytechnic University of Valencia (Miguel Miranda’s group, UPV) team is headed by a world leader in Photochemistry, the University of Oslo partner (Hanne H. Tønnensen’s group, UiO) is specialized in pharmaceutical formulation, and Knight Scientific Ltd (KSL, CEO Jan Knight) is an SME with an impressive track record in ROS-activated luminescence. This 4.5-year project will establish the Lumiblast breakthrough technology by providing proof-of-concept in extracellular systems, GBM cell cultures and animal models, with the vision to advance Lumiblast to the clinic 5-6 years after the end of the proposed project.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2019-05-31 16:51:01

Take a look to the deliverables list in detail:  detailed list of Lumiblast deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Pantelia, Daskalaki, Cuquerella, Rotas, Miranda, Vougioukalakis
Synthesis and Chemiluminescent Properties of Amino-Acylated luminol Derivatives Bearing Phosphonium Cations
published pages: 3957, ISSN: 1420-3049, DOI: 10.3390/molecules24213957
Molecules 24/21 2020-04-04
2020 Mantas Grigalavicius, Maria Mastrangelopoulou, Delmon Arous, Asta Juzeniene, Mathilde Ménard, Ellen Skarpen, Kristian Berg, Theodossis A. Theodossiou
Photodynamic efficacy of cercosporin in 3D tumor cell cultures
published pages: , ISSN: 0031-8655, DOI: 10.1111/php.13257
Photochemistry and Photobiology 2020-04-04
2019 Maria Mastrangelopoulou, Mantas Grigalavicius, Kristian Berg, Mathilde Ménard, Theodossis A. Theodossiou
Cytotoxic and Photocytotoxic Effects of Cercosporin on Human Tumor Cell Lines
published pages: 387-396, ISSN: 0031-8655, DOI: 10.1111/php.12997
Photochemistry and Photobiology 95/1 2019-04-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUMIBLAST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LUMIBLAST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

EDRA (2019)

Hardware-Assisted Decoupled Access Execution on the Digital Market: The EDRA Framework

Read More  

BioProMarL (2019)

Bio-inspired Protection of Marble with Lasers

Read More  

LABELFREE (2019)

LABEL FREE IMAGING WITH PHI-SCAT

Read More